{"organizations": [], "uuid": "cca9c6f22f027cd68b78d5d2c93cdfb5c3bd9bc5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tesaro-collaborates-with-roche-to/brief-tesaro-collaborates-with-roche-to-evaluate-their-combination-treatment-for-bladder-cancer-idUSFWN1QG19D", "country": "US", "domain_rank": 408, "title": "BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T22:05:00.000+02:00", "replies_count": 0, "uuid": "cca9c6f22f027cd68b78d5d2c93cdfb5c3bd9bc5"}, "author": "", "url": "https://www.reuters.com/article/brief-tesaro-collaborates-with-roche-to/brief-tesaro-collaborates-with-roche-to-evaluate-their-combination-treatment-for-bladder-cancer-idUSFWN1QG19D", "ord_in_thread": 0, "title": "BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "tesaro inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 26, 2018 / 8:07 PM / Updated 4 minutes ago BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer Reuters Staff 1 Min Read Feb 26 (Reuters) - Tesaro Inc: * TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER * TESARO INC - ‍PLANNED TRIAL WILL BE CONDUCTED BY GENENTECH AND IS EXPECTED TO BEGIN MID-2018​ * TESARO INC - ‍COLLABORATION INCLUDES TESTING EXPERIMENTAL COMBINATION IN MORPHEUS, ROCHE‘S CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-26T22:05:00.000+02:00", "crawled": "2018-02-26T22:24:47.016+02:00", "highlightTitle": ""}